GSK and Sabin Signs an Exclusive Agreement to Advance the Development of Ebola and Marburg Vaccines

Shots:

Sabin to get an exclusive technology license for all three vaccine candidates i.e, Ebola Zaire, Ebola Sudan and Marburg vaccines and patent rights related to vaccines
In 2013, GSK acquired three vaccines from the US NIH & Okairos. The candidates are based on GSK’s ChAd3 platform and were developed by GSK including P-II development of Ebola Zaire vaccine
Additionally, Sabin has collaborated with VRC at NIAID to advance ChAd3 Ebola and Marburg vaccines and has evaluated them in multiple trials in 5,000+ adults & 600+ children which demonstrated high immunogenicity among the population

Click here to read full press release/ article | Ref: GSK | Image: Boston Africa